

May 18, 2017

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Sirs,

Sub: *Strides Shasun announces Joint Ventures with Vivimed Labs*

We are pleased to inform you that the Company has signed definitive agreements with Vivimed Labs to set up two Joint Venture Companies, as under:


- The 50:50 Joint Venture Company in India will own the US FDA approved formulation facility in Alathur, Chennai and
- The 50:50 Joint Venture Company in Singapore through Strides Pharma Global Pte Limited, Singapore will own certain approved ANDAs and product pipeline.

The transaction is subject to customary closing conditions and expected to close by 31st May 2017.

Please find enclosed disclosure under Regulation 30 of SEBI (LODR) on the proposed Joint Venture.


Thanks & Regards,
For **STRIDES SHASUN LIMITED**

Manjula R
Manjula Ramamurthy
Company Secretary



Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars		
1.	Name of the Target entity, details in brief such as size, turnover etc.	Vivimed Life Sciences Private Limited, India Size, Turnover: Not applicable	
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	No	
3.	Industry to which Target entity being acquired belongs	Pharmaceuticals	
4.	Objects and effects of acquisition	Provides additional capacity and de-risking manufacturing infrastructure. The purpose of investment is to form a Joint Venture with Vivimed Labs. The JV Company will own the US FDA approved formulation facility in Alathur, Chennai.	
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None	
6.	Indicative time period for completion	Expected to close by May 31, 2017	
7.	Nature of consideration	Cash	
8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	50%	
9.	Cost of acquisition or the price at which the shares are acquired	INR 66 Crores	
10.			
a.	Products/line of business acquired	Pharmaceutical formulations	
b.	Date of incorporation	20/02/2017	
c.	History of last 3 years turnover	FY 2015-16	NA
		FY 2014-15	NA
		FY 2013-14	NA
d.	Country in which the acquired entity has presence	India	
e.	Any other significant information	None	



Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars		
1.	Name of the Target entity, details in brief such as size, turnover etc.	Vivimed Global Generics Pte Ltd., Singapore Size, Turnover: Not applicable	
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	No	
3.	Industry to which Target entity being acquired belongs	Pharmaceuticals	
4.	Objects and effects of acquisition	Provides access to a strong product pipeline The purpose of investment is to form a Joint Venture with Vivimed Labs. The JV Company will own certain approved ANDAs and product pipeline.	
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None	
6.	Indicative time period for completion	Expected to close by May 31, 2017	
7.	Nature of consideration	Cash	
8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	50%	
9.	Cost of acquisition or the price at which the shares are acquired	INR 9 Crores	
10.			
a.	Products/line of business acquired	Pharmaceutical formulations	
b.	Date of incorporation	17/04/2017	
c.	History of last 3 years turnover	FY 2015-16	NA
		FY 2014-15	NA
		FY 2013-14	NA
d.	Country in which the acquired entity has presence	Singapore	
e.	Any other significant information	The investment will be made through Strides Pharma Global Pte Limited, Singapore.	

